Understanding What is the Mechanism of Action of Rituximab?
•
2 min read
First approved by the FDA in 1997 for non-Hodgkin lymphoma, the anti-CD20 monoclonal antibody rituximab has since revolutionized treatment for a variety of B-cell malignancies and autoimmune disorders. Understanding **what is the mechanism of action of rituximab** reveals a multifaceted process involving several distinct cytotoxic pathways to eliminate B-cells.
